Pierre Fabre
New ways to care  

Lavaur (France), July 1, 2026 – Laboratoires Pierre Fabre announces the appointment of Venaïg  Solinhac as CEO of its Dermo‑Cosmetics and Personal Care division. In this role, she joins the executive committee of Laboratoires Pierre Fabre and reports to Eric Ducournau, Group CEO. Venaïg Solinhac brings more than 20 years of international experience driving growth and transformation for global leaders in consumer healthcare, consumer goods, and venture capital. She has held key executive positions at Kenvue, notably as Global Vice President of Baby Care (based in New York) and Vice President of Essential Health Asia Pacific (based in Singapore). There, she delivered tangible results: the global relaunch of Johnson’s Baby, the revitalization of Listerine in Asia‑Pacific, and the rollout of large-scale digital and commercial acceleration programs. Previously, she spent 15 years at GlaxoSmithKline Consumer Healthcare, where she held local, regional, and global leadership roles across four continents. There, she led transformative portfolio and digitalization initiatives, contributing to the growth of major brands such as Sensodyne, Panadol, Centrum, and Parodontax. As part of the Scale Up 2032 plan, Venaïg  Solinhac will lead the development and implementation of the strategy for Pierre Fabre’s Dermo‑Cosmetics and Personal Care division—Eau Thermale Avène, Ducray, A‑Derma, Klorane, René Furterer, Darrow, MÊME Cosmetics, and Pierre Fabre Oral Care. Backed by recommendations from dermatologists and pharmacists, these brands deliver expert, recognized solutions with high clinical value for sensitive and compromised skin (wound healing, eczema, acne, and the effects of cancer treatments), as well as leading solutions in oral health. In 2025, the business generated revenue of 1.711 billion euros (+2.6% vs. 2024), up +4.4% (at constant exchange rates). 

Back in 2009, Ducray was already pioneering  pharmacy refills with its iconic EXTRA-DOUX shampoo. Castres, 11June 2026 – To mark World Refill Day on 16 June, Laboratoires Pierre Fabre highlights the key role that reducing packaging and developing refill solutions in pharmacies has played for many years in its environmental responsibility approach. Driven by a portfolio of iconic dermo-cosmetic brands distributed worldwide — Avène, A-Derma, Ducray, Klorane and René Furterer —, Laboratoires Pierre Fabre has been implementing initiatives for over 15 years to reduce and limit the use of plastic, encourage reuse and guide consumers towards more responsible daily skincare habits, without compromising on quality or safety. 

The Avène catchment area and its thermal hydrosystem have been recognised as a site of geological interest within the Terres d’Hérault Geopark, designated a “UNESCO Global Geopark” Avène, 5th June 2026 – The “Terres d’Hérault” region has just been officially designated a UNESCO Global Geopark, in recognition of its exceptional geological wealth and the collective commitment of its stakeholders to the protection and promotion of this heritage.At the heart of this 2,046 km² area, comprising 58 remarkable geosites, lies the Avène catchment area, the place where Avène thermal spring water springs forth. This catchment area and its thermal hydrosystem are now recognised as a site of interest within the Terres d’Hérault Geopark. This decision reinforces the efforts of the API’A (Association pour la préservation de l’impluvium des eaux d’Avène) to promote understanding, preservation and enhancement of this exceptional area, which is now officially recognised. For over 50 years, Eau Thermale Avène brand has made understanding and preserving water resources one of its priorities. It has developed a robust scientific programme led by the Water Laboratory, a true multidisciplinary center of expertise dedicated to Avène thermal spring water: scientific and geological studies, mineral and microbiological analysis of the water, and pharmacological and clinical research.

Avène (France), 28 May 2026 – As part of its new industrial master plan, Laboratoires Pierre Fabre has reached a major milestone by announcing a strategic investment of nearly €50 million to transform and expand its production site in Avène-les-Bains (Hérault in France), which is fully dedicated to the manufacturing and packaging of Eau Thermale Avène products. This project reflects the company’s ambition to upgrade its sites into next generation factories that are more modern, more automated and less resource intensive, capable of sustainably supporting growth while reducing their environmental footprint.

Castres (France), May 26, 2026 - Pierre Fabre Participations, the Group’s parent holding company, has appointed Hervé Hoppenot as Chairman of the Board of Pierre Fabre SA. The Board of Directors, which met on May 21, approved this appointment. Hervé Hoppenot, who has served as a Board member of Pierre Fabre SA since January 15, 2024, succeeds Roch Doliveux, who has been appointed Vice Chairman of the Board. Hervé Hoppenot, 65, a dual French-American citizen, has spent most of his career in the United States. He served as Chair and CEO of the US biotechnology company Incyte from 2014 to 2025, gradually transforming it into a major player in the field of onco-hematology. Previously, he served as President of the Novartis Global Oncology franchise, where he oversaw one of the pharmaceutical industry’s largest portfolios of cancer prescription drugs. In addition to his new role at Pierre Fabre, Hervé Hoppenot also serves as Chair of the Board of Directors of the California-based biotech company Maze Therapeutics and as a director of two other biotech companies: Bicycle Therapeutics and N-Power Medicine. Pierre Yves Revol, Chairman of the Board of Pierre Fabre Participations, said:

In line with Pierre Fabre Laboratories' vision "Every time we care for a single person, we make the whole world better" the MSL (Medical Science Liaison) role is crucial in enhancing patient care. As a scientific bridge between the medical community and the Pierre Fabre Laboratories, the MSL combines pharmaceutical innovation with medical expertise to develop collaboration with healthcare professionals and optimize daily healthcare practices. The MSL's objectives can be achieved through various missions, including: Medical Education: promoting best practices for up-to-date patient management. Insight Collection: gaining a comprehensive understanding of patient treatment practices, organization, and patient journey. Data Needs Identification and participation to their generation to promote best practices for patient treatment. Support Clinical Development and Real-World Evidence Projects. Understanding patient needs.

From March 13 to 16, our teams were present at ExCeL London to participate in the annual congress of the European Association of Urology (EAU). This major international event once again provided an opportunity to highlight our long-standing expertise in urology and to reinforce our commitment alongside healthcare professionals. The 2026 edition of the EAU congress brought together the global scientific community around the latest advances in urology: innovations, clinical studies, new guidelines, and emerging therapeutic perspectives. Our presence in London also underscored more than 40 years of continuous commitment to this essential medical specialty.Throughout the congress, our teams had the opportunity to engage with healthcare professionals and key opinion leaders from around the world. These exchanges enabled us to share our vision and reaffirm our determination to support the evolution of care for urinary disorders. It was also a key moment to reaffirm our ambition: to deliver innovations and sustainably improve patients’ quality of life.Beyond the scientific presentations and plenary sessions, the congress confirmed the central role of the urological ecosystem in driving innovation. We are proud to have contributed to the discussions shaping the future of the specialty and to continue working alongside the international medical community. Compliance StatementPierre Fabre Médicament is a sponsor of this event but has had no input into the overall agenda or scientific content of the meeting, other than a sponsored promotional symposium and exhibition stand.UK--03-26-2600010        03/2026